FTC Says Endo, Impax Cut 2nd Opana ER Pay-For-Delay Deal
The Federal Trade Commission filed a new antitrust complaint Monday accusing Endo Pharmaceuticals and Impax Laboratories of striking a second deal to stave off competition to the Opana ER opioid pain...To view the full article, register now.
Already a subscriber? Click here to view full article